Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients

Liver Transplantation

Volumn 22, Issue 11, 2016, Pages 1536-1543

  Kwok, Ryan M ^a   Ahn, Joseph ^b   Schiano, Thomas D ^c   Te, Helen S ^d   Potosky, Darryn R ^e   Tierney, Amber ^f   Satoskar, Rohit ^a   Robertazzi, Suzanne ^a   Rodigas, Colleen ^a   Lee Sang, Michelle ^a   Wiegel, Joshua ^b   Patel, Neal ^c   Gripshover, Janet ^e   Hassan, Mohamed A ^f   Branch, Andrea ^c   Smith, Coleman I ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CALCINEURIN INHIBITOR; CREATININE; HEMOGLOBIN; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG COMBINATION; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ARTHRALGIA; ARTICLE; BACTEREMIA; BODY WEIGHT DISORDER; BRAIN DISEASE; CAUCASIAN; CHEMICAL INJURY; COUGHING; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENDOCARDITIS; FATIGUE; FEMALE; GENOTYPE; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; HYPERKALEMIA; HYPONATREMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL SCHOOL; MENTAL DISEASE; MULTICENTER STUDY; MYALGIA; NAUSEA; PANCREATITIS; PERICARDITIS; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; THORAX PAIN; TREATMENT RESPONSE; VOMITING; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG COMBINATION; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; VIROLOGY;

AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CALCINEURIN INHIBITORS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PRAGMATIC CLINICAL TRIALS AS TOPIC; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; URIDINE MONOPHOSPHATE;

EID: 84992468359     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24614     Document Type: Article

References (15)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333–1342.
2. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32(pt 1):852–858.
3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889–896.
4. Perrakis A, Yedibela S, Schuhmann S, Croner R, Schellerer V, Demir R, et al. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin. Transplant Proc 2011;43:3824–3828.
5. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006;6:1586–1599.
6. Burton JR Jr, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014;61:508–514.
7. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. for ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889–1898.
8. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al.; for ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–1493.
9. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al.; for ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–1888.
10. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al.; for SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649–659.
11. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015;61:1880–1886.
12. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014;371:2375–2382.
13. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology 2016;63:1493–1505.
14. Antiviral Society–USA.American Association for the Study of Liver Diseases, Infectious Diseases Society of America, International Recommendations for Testing, Managing, and Treating Hepatitis C. www.hcvguidelines.org. Accessed July 20, 2016.
15. Jacobson I, Gordon S, Kowdley K, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867–1877.